3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
127
Colonic Neoplasms
54
Rectal Neoplasms
49
Carcinoma, Hepatocellular
29
Stomach Neoplasms
22
Neoplasm Metastasis
22
Neoplasms
11
Pancreatic Neoplasms
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Gastrointestinal Neoplasms
4
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Adenocarcinoma
3
Unresectable Metastatic Colorectal Cancer
2
Peritoneal Neoplasms
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled